Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
The company’s largest center for medical device applications, serving the entire Asian market
Subscribe To Our Newsletter & Stay Updated